# Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

> **NCT07043608** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Kelly Fitzgerald, MD** · enrollment: 20 (estimated)

## Conditions studied

- Clear Cell Renal Cell Cancer (ccRCC)
- Clear Cell Renal Carcinoma
- Clear Cell Renal Cell Carcinoma Metastatic
- Clear Cell Renal Cancer
- Bone Metastases of a Malignant Tumor
- Clear Cell Renal Cell Carcinoma
- Bone, Metastatic Cancer
- Metastatic Cancer
- Metastatic Renal Cell Carcinoma
- Metastases to Bone

## Interventions

- **DRUG:** Zanzalintinib
- **DRUG:** Investigator Choice of Bone Strengthening Agents (BSA)
- **RADIATION:** Non-Investigational Radiation Therapy (RT)
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computerized tomography (CT) Scan

## Key facts

- **NCT ID:** NCT07043608
- **Lead sponsor:** Kelly Fitzgerald, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2029-02-28
- **Final completion:** 2030-02-28
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07043608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07043608, "Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07043608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*